ProCE Banner Activity

Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

Podcast Episodes
In this podcast episode, listen to Miguel A. Escobar, MD; Mark Reding, MD; and Guy A. Young, MD, answer questions from a healthcare professional audience related to the use of current and emerging treatments for patients with hemophilia A.

Released: January 14, 2022

Expiration: January 13, 2023

No longer available for credit.

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark Reding

Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Guy A. Young

Guy A. Young, MD

Professor of Pediatrics
University of Southern California
Keck School of Medicine
Director
Hemostasis and Thrombosis Center
Childrens Hospital Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme

Takeda Pharma USA Inc Takeda Onc Co

Program Director Disclosure

Program Director

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received funds for research support from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure (paid to institution) and consulting fees from CSL Behring, BioMarin, Genentech/Roche, HEMA Biologics , Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda.

Faculty Disclosure

Primary Author

Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Mark Reding, MD, has disclosed that he has received consulting fees from Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme, and Takeda; funds for research support from Bayer and Biomarin; and fees for non-CME/CE services from Bayer, CSL Behring, Sanofi Genzyme, and Takeda.

Guy A. Young, MD

Professor of Pediatrics
University of Southern California
Keck School of Medicine
Director
Hemostasis and Thrombosis Center
Childrens Hospital Los Angeles
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Hema Biologics, Kedrion, Novo Nordisk, Sanofi, Spark, and Takeda.